Compare Expedia Group Inc (EXPE) vs HCA Health Inc (HCA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs HCA Health Inc — how do they compare? Expedia Group Inc trades at $269.5 (market cap $31.07B), while HCA Health Inc trades at $443.69 (market cap $95.08B). The key difference: HCA Health Inc is far larger — about 3.1× Expedia Group Inc's market cap, and Expedia Group Inc pays the higher dividend (0.74%). Which is the better fit depends on your goals — on Pluang, investors hold Expedia Group Inc for 48 Days and HCA Health Inc for 76 Days on average.
| EXPE | HCA | |
|---|---|---|
Market Cap | $31.07B | $95.08B |
Volume | 1,305,431 | 998,787 |
Sector | Consumer Cyclical | Health |
52-Week High | $339.13 | $545.13 |
52-Week Low | $188.51 | $361.32 |
Typical Hold Time | 48 Days | 76 Days |
Enterprise Value | $29.63B | $145.62B |
Dividend Yield | 0.74% | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $270.13, up 3.95% today, with strong earnings beats in recent quarters but facing technical bearish signals. The company shows robust fundamentals with 2025 revenue of $14.73B, net income of $1.29B, and healthy cash flow generation. Recent news highlights competitive threats from AI travel agents and workforce reductions, while analyst consensus remains mixed with a $335.06 price target.
EXPE presents a valuation opportunity with P/E of 16.28 below sector averages, but faces significant headwinds from AI disruption in travel booking. The stock's 199% ROE and consistent earnings outperformance support long-term growth potential, though near-term technical weakness and competitive pressures require careful monitoring.
HCA Healthcare (HCA) trades at $445.01, up 2.96% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $75.6B in 2025, with net income of $6.78B, and the stock trades at a P/E of 14.73. Analyst consensus is a Buy with a $461.12 price target, though ongoing legal investigations pose a headwind.
The outlook remains positive given solid demand and cost controls, but risks include payer-mix pressure and high debt levels. Upside potential exists if earnings growth continues, but investors should monitor legal developments and interest rate impacts on the leveraged balance sheet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →
